Sarepta Therapeutics, Inc.
—- Market cap
- —
- Debt
- +$828.97M
- Cash
- −$939.65M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SRPT stock price vs BN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BN's multiple
Needs BN P/S.
Implied fair value · at SRPT's multiple
Needs Revenue / share, SRPT P/S.
Metric by metric
Snapshot Sep 8, 2026, 2:36 PM ET
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · BN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SAREPTA THERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BROOKFIELD CORPORATION · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.73x
—
Net debt / EBITDA
Leverage against operating earnings
0.17x
95.68x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$16.24B
Total debt
Interest-bearing obligations outstanding
$828.97M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
BXP, Inc.
SRPT vs BXP
SL GREEN REALTY CORP
SRPT vs SLG
HIGHWOODS PROPERTIES, INC.
SRPT vs HIW
CBRE GROUP, INC.
SRPT vs CBRE
JONES LANG LASALLE INC
SRPT vs JLL
KILROY REALTY CORP
SRPT vs KRC
$325.77B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.